NCT03779191View on ClinicalTrials.gov

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 8, 2020

Primary Completion Date

August 1, 2022

Study Completion Date

October 30, 2022

Conditions
ALK Gene Rearrangement PositiveNon-Squamous Non-Small Cell Neoplasm of Lung
Interventions
DRUG

Alectinib

Alectinib dosed 600 mg twice a day (BID) with meals until disease progression, unacceptable toxicity, or other reasons specified in the protocol

DRUG

Bevacizumab

Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol

Trial Locations (1)

14080

Instituto Nacional de Cancerologia, Mexico City

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Instituto Nacional de Cancerologia de Mexico

OTHER

NCT03779191 - Alectinib in Combination With Bevacizumab in ALK Positive NSCLC | Biotech Hunter | Biotech Hunter